The ADDF seeks to support comparative effectiveness research, clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.



Average Duration: 1-2 years
Average Award: Varies
- Epidemiological Analyses: $50,000-$100,000
- Clinical Trials: up to $3 million


Must be received by 11:59 pm EST on the deadline date.

Letter of Intent: February 17, 2017
Invited Full Proposal: March 10, 2017

Letter of Intent: May 19, 2017
Invited Full Proposal: June 9, 2017

Letter of Intent: July 31, 2017
Invited Full Proposal: September 8, 2017

Letter of Intent: November 17, 2017
Invited Full Proposal: December 8, 2017

Prevention Research Funding Priority Areas

  • Consortium of Cohorts for Alzheimer's Prevention Action (CAPA) – Epidemiological studies contribute unmatched information on whether the risk of dementia or cognitive decline may be influenced by long-term exposure to specific foods, supplements, and drugs. However, high-powered studies are needed, ideally with dose, duration, and responder profiles, in order to translate epidemiological research into actionable interventions for testing. Through the CAPA Consortium, the ADDF funds collaborative analyses on dementia prevention using a minimum of five longitudinal cohorts, either harmonized or analyzed through parallel analysis of cohorts using a shared analysis script. More information here.
  • Comparative Effectiveness Research – For many health conditions, physicians have a choice of clinically equivalent drugs. Some of these drugs are being investigated for repurposing to treat Alzheimer's or related dementias, due to potential disease-modifying properties that go beyond their treatment of their approved disease indication. The ADDF will consider funding research to generate an evidence base on whether choices in the routine clinical care of pre-existing conditions could protect against dementia. Priority will be given to the comparison of drugs that are otherwise clinically equivalent for the pre-existing condition (see Box 1 in the ADDF 2016 position paper). Methods may include randomized clinical trials or epidemiology.
  • Cognitive Decline and Cognitive Reserve – Cognitive decline through aging and health conditions has been linked to an increased risk of dementia. The ADDF will consider funding drug discovery programs to prevent and treat these conditions, including cognitive aging, postoperative delirium and postoperative cognitive decline, mild and/or repetitive traumatic brain injury, and chemotherapy-induced decline. Methods may include clinical trials or epidemiology.

Funding Eligibility

  • Academic Investigators seeking to create and support innovative programs in academic medical centers and universities.
  • Biotechnology companies with programs dedicated to Alzheimer's disease translational development – New biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for non-profit funding are eligible to apply. Funding is provided through mission-related investments (MRIs) that require return on investment based upon scientific and/or business milestones.

Application Submission Guidelines

Review the Application Instructions before applying.

The ADDF typically supports one to two years of research at a time, with potential for future follow-on funding. Funding can range from $50,000-$100,000 for epidemiological analyses and up to $3 million for clinical trials. Budgets must be justified by the scientific work plan. In some cases, multi-year proposals are considered.

All applicants are required to complete an electronic "Letter of Intent" (LOI) in the ADDF Funding Portal.




For program-related inquiries, please contact:
Yuko Hara, PhD, Acting Director, Aging and Alzheimer's Prevention
Phone: 212.901.8000

For application submission inquiries, please contact:
Grants and Contracts Team
Phone: 212.901.7998